Skip to main content
OpenTrials
Completed

NCT Number: NCT05059353

Effectiveness and Safety of a Digitally Based Multidomain Intervention for Mild Cognitive Impairment

This study is designed to evaluate the preliminary effectiveness and safety of a digitally based multidomain intervention in patients with MCI. In addition, a portion of cognitively normal subjects and caregivers of patients with MCI will also be recruited as an exploratory cohort. We hope that the digital platform will improve the overall cognition and quality of life in patients with MCI.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Mild Cognitive Impairment Cognition Disorders Cognitive Dysfunction Mental Disorders Neurocognitive Disorders

Age range

50 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

National Neuroscience Institute

Singapore, 308433

About this study

3 groups of participants will be recruited. For the participants in the MCI (group A) and cognitively normal subjects (group B), they will be provided with a digital tablet and a wearable device. The digital tablet will be pre-loaded with 10 modules, 1 module per week (1 hour) for 10 weeks to be completed at home. The wearable device will be used to track and collect physiological data.

For the caregivers of the patients with MCI (group C), they will be asked to complete a questionnaire during screening visit and follow-up visit, and to use the caregiver app during the intervention period.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Patients with MCI Thirty (30) patients with MCI of the amnestic type (single or multi domain) will be recruited. MCI will be diagnosed using the Petersen's criteria and/or the NIA-AA criteria by cognitive neurologists.

Inclusion criteria

  • Either male or female aged between 50 and 70 years (inclusive)
  • Diagnosis of amnestic MCI using the Petersen's criteria and/or the NIA-AA criteria
  • Clinical Dementia Rating (CDR) score of 0.5 and Mini-Mental State Examination (MMSE) >24
  • Education >6 years
  • Literate in English
  • Basic proficiency in using web-based applications/mobile platforms
  • Willing to give informed consent

Exclusion criteria

  • Significant hearing or visual impairment
  • Significant systemic, neurological or psychiatric illness such as end stage renal failure, Parkinson's disease or major depression.
  • Participation in any pharmacological or non-pharmacological (interventional) clinical trial in the preceding 12 weeks

Cognitively Normal Subjects Ten (10) cognitively normal subjects will be recruited.

Inclusion criteria

  • Either male or female aged between 50 and 70 years (inclusive)
  • CDR of 0 and MMSE > 27
  • Education >6 years
  • Literate in English
  • Basic proficiency in using web-based applications/mobile platforms
  • Willing to give informed consent

Exclusion criteria

  • Significant hearing or visual impairment
  • Significant systemic, neurological or psychiatric illness such as end stage renal failure, Parkinson's disease or major depression.
  • Participation in any pharmacological or non-pharmacological clinical trial in the preceding 12 weeks

Caregivers of Patients with MCI Fifteen (15) caregivers of the 30 patients with MCI will be recruited.

Inclusion criteria

  • Either male or female aged ≥21 years
  • Is the spouse or child of the patient and must spend at least 2 hours per week with the patient.
  • Must be healthy and not suffering from any serious systemic, neurological or psychiatric illness.
  • Literate in English
  • Willing to give informed consent Exclusion criteria: NA

Treatment and study plan

Digitally based multidomain intervention

Device

Education (5-10 mins). This session is to educate patients on instrumental activities of daily living such as the importance of companionship, medication, finance, home, travel, and kitchen safety. The content will be delivered using video and text-based material in English.

Physical Activity (10 mins). This session includes activities such as brisk walking and yoga. Participants will be allowed to choose their preferred exercise option from the menu.

Reminiscence Therapy (20 mins). This session includes recollection of events using directed questions, and a collection of photos from the past. Participants will be asked to share about any aspect related to the given topics using text or audio.

Cognitive Games (20 mins). Participants will be asked to play games using their fingers to control characters on the screen to achieve goals. These games are designed to train different cognitive abilities, including attention, memory, executive functioning, and processing speed.

Primary outcomes

  1. Change from baseline in processing speed

    Time frame: Baseline compared to Week 11

    Using Neuropsychological Test Battery (NTB) Processing Speed domain items (symbol digit modalities test, trail making test A, and Stroop test (condition 1 and 2) in patients with MCI

  2. Change from baseline in executive functioning

    Time frame: Baseline compared to Week 11

    Using the NTB Executive Function domain items (digit span test, verbal fluency test, similarities test from Wechsler Adult Intelligence Scale IV (WAIS-IV) and trail making test B) in patients with MCI

  3. Change from baseline in mood using the Depression Anxiety Stress Scales (DASS-21) in patients with MCI

    Time frame: Baseline compared to Week 11

    The Depression, Anxiety and Stress Scale - 21 Items (DASS-21) is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress.

    Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content.

    The scoring ranges from 0 to 3 per item. The higher the score, the greater the sense of depression, anxiety or stress.

Secondary outcomes

  1. Change from baseline in overall cognition in patients with MCI

    Time frame: Baseline compared to Week 11

    Overall cognition is tested using the Neuropsychological Test Battery (NTB). Higher scores demonstrates better performance.

  2. Change from baseline in QoL

    Time frame: Baseline compared to Week 11

    Using QOL-AD questionnaire in patients with MCI

Sponsors and collaborators

Lead sponsor

Neuroglee Therapeutics

Industry

Registry information

Official study title

Open Label Clinical Trial to Study the Effectiveness and Safety of a Digitally Based Multidomain Intervention for Mild Cognitive Impairment

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Sep 28, 2021
Registry last updated
Oct 13, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.